31.05MMarket Cap1.28P/E (TTM)
1.810High1.750Low8.69KVolume1.770Open1.770Pre Close15.40KTurnover0.06%Turnover RatioLossP/E (Static)17.64MShares12.68052wk High2.20P/B24.28MFloat Cap1.50052wk Low--Dividend TTM13.80MShs Float360.000Historical High--Div YieldTTM3.39%Amplitude1.500Historical Low1.772Avg Price1Lot Size
Incannex Healthcare Stock Forum
Incannex Healthcare Inc - FDA Approves Phase 2 Clinical Trial for Incannex
Dosing Completed in 115 Participant Bioavailability/Bioequivalence
Patient dosing commenced in RePOSA Phase 2/3 Clinical Trial Protocol to Assess IHL-42X Drug in Patients with Obstructive Sleep Apnea
Incannex Healthcare Inc. (Nasdaq: IXHL), biotechnology company, specializing in cannabinoid and psychedelic medicine, marked a significant milestone on May 7, 2024, with the successful completion of a pre-Investigational New Drug (pre-IND) meeting with the U.S. Food and Drug Administration (FDA). This crucial step forward perta...
Incannex Complete Successful Pre-Ind Meeting With the FDA for Cannquit-O for Treatment of Opioid Use Disorder
NEWS
Stonegate Healthcare Partners Releases Report on Potentially Transformative Therapies for Generalized Anxiety Disorder (GAD)
Stonegate Healthcare Partners has released a report on potentially transformative therapies for Generalized Anxiety Disorder (GAD), aiming to improve patients' quality of life. The report highlights leading programs by companies like Mindmed, Incannex (NASDAQ: IXHL), and Compass Pathways. The global market for GAD treatment is projected ...
No comment yet